Mcbarron Paul Insider Trades

Insider Trading History

Track insider trading activity for Mcbarron Paul. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
See Remarks
Holding Value $169k 33,378 shares
Last Trade
Dec 21, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$30.6k 1,886 shares
$16.20
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $212k 33,378 shares
Last Trade
Dec 21, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.63M 1,886 shares
$864.00
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $447k 70,200 shares
Last Trade
Jun 30, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$149M 70,200 shares
$2,119.70
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
E. Vp, Fin, Cfo, COO And Secretary
Holding Value $355k 70,200 shares
Last Trade
Jun 30, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$892k 70,200 shares
$12.70
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $200k 31,492 shares
Last Trade
Jan 31, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$101M 31,200 shares
$3,252.05
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
E. Vp, Fin, Cfo, COO And Secretary
Holding Value $159k 31,492 shares
Last Trade
Jan 31, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$377k 31,200 shares
$12.09
$5.05
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
E. Vp, Fin, Cfo, COO And Secretary
Holding Value $505k 100,000 shares
Last Trade
Dec 13, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$608k 100,000 shares
$6.08
$5.05
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
E. Vp, Fin, Cfo, COO And Secretary
Holding Value $606k 120,000 shares
Last Trade
Dec 11, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$864k 120,000 shares
$7.20
$5.05
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
E. Vp, Fin, CFO And COO
Holding Value $65.8k 13,022 shares
Last Trade
Dec 05, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$106k 25,002 shares
$4.25
$5.05
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $1.36M 270,079 shares
Last Trade
Jan 04, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.67M 270,079 shares
$6.20
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $1.66M 260,432 shares
Last Trade
Dec 07, 2015 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$133B 260,432 shares
$508,845.01
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $1.32M 260,432 shares
Last Trade
Dec 07, 2015 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.26M 260,432 shares
$4.84
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $338k 53,095 shares
Last Trade
Feb 18, 2015 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$39.4B 53,095 shares
$742,965.55
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $446k 70,000 shares
Last Trade
Dec 09, 2013 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$279B 70,000 shares
$3,982,640.90
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $446k 70,096 shares
Last Trade
May 21, 2013 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$34.3B 12,948 shares
$2,652,214.22
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $1.67M 263,054 shares
Last Trade
Dec 06, 2011 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$376B 75,000 shares
$5,019,337.01
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $1.2M 188,054 shares
Last Trade
Sep 23, 2011 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$36.3B 12,000 shares
$3,023,697.00
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $477k 75,000 shares
Last Trade
Dec 10, 2010 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$721B 75,000 shares
$9,615,356.44
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
See Remarks
Holding Value $955k 150,000 shares
Last Trade
Nov 18, 2008 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$400B 150,000 shares
$2,666,900.75
$6.36

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up